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Background: Hepatocellular carcinoma (HCC) is regarded as one of the most common malignancies and among
the leading causes of cancer death among the whole world. The most urgent needs are to find sensitive markers
for early diagnosis or monitor postoperative recurrence and to give adequate treatment for HCC. MicroRNAs
(miRNAs) are reported as a group of small non-coding RNAs that can function as endogenous RNA interference to
regulate expression of the targeted genes. This study was conducted to detect the application of miR-143 and
miR-215 in the diagnosis of HCC.
Methods: A total of 340 serum samples (127 samples from controls, 118 samples from hepatitis and 95 samples
from HCC patients) were collected. The levels of the two mature miRNAs (miR-143 and miR-215) were detected by
probe-based stem-loop quantitative reverse-transcriptase PCR (RT-qPCR) in controls, hepatitis and HCC patients.
Besides, the relationship between miR-143 and miR-215 levels and clinical and pathological factors was explored.
Results: We found that the expression of serum miR-215 was distinctly increased in chronic hepatitis compared
with controls (mean ± SD: 6.79 ± 0.72 vs. 3.46 ± 0.37, P < 0.001 and mean ± SD: 8.38 ± 0.87 vs. 3.46 ± 0.37, P < 0.001).
In addition, we conduct ROC analyses to detect the potential application of miR-143 and miR-215 in the diagnosis
of chronic hepatitis and HCC. Our results showed that miR-143 and miR-215 might be a potential biomarker for the
hepatitis and HCC.
Conclusions: In conclusion, the expression of miR-143 and miR-215 in serum were significantly up-regulated in
patients with chronic hepatitis and HCC. Due to its reasonable sensitivity and specificity for both diseases, miR-143
and miR-215 could be as potential circulating biomarkers.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1048932281272754Background
Hepatocellular carcinoma (HCC) is regarded as one of
the most common malignancies and among the leading
causes of cancer-related deaths among the whole world,
especially in East Asia and South Africa [1,2]. HCC
ranks the second in China among all malignancies and
its mortality is almost equal to its morbidity [3,4]. The
carcinogenesis of HCC is a multifactor, multi-step, complex* Correspondence: yonglu_09@163.com; yongluango@163.com
2Department of Gastroenterology, the First Affiliated Hospital of Dalian
Medical University, Dalian 116011, China
4Department of Anesthesiology, the First Affiliated Hospital of Dalian Medical
University, Dalian 116011, China
Full list of author information is available at the end of the article
© 2014 Zhang et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.process and it is associated with a background of chronic
liver diseases or persistent infection of hepatitis B virus
(HBV) or hepatitis C virus (HCV), along with alcohol
drinking which are widely recognized etiological agents in
HCC. However, the underlying mechanisms that lead to
malignant transformation of infected cells remained
unclear by now. Most HCC patients died quickly because
of the rapid tumor progression and hepatic resection or
transplantation is the only potential curative treatment for
HCC patients. By now, surgery remains the best prognos-
tic tool for long-term survival of HCC patients; however,
more than 80% of patients with HCC have underlying
cirrhosis, and of these patients, only 10% to 15% areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of size, location or severity of underlying liver disease. The
most urgent needs are to find sensitive markers for early
diagnosis or monitor postoperative recurrence and to give
adequate treatment for HCC.
Up to now, although serum alpha-fetoprotein (AFP)
level is a useful tumor marker for the detection and
monitoring of HCC, the false negative rate with AFP
level alone may be as high as 40% for patients with early
stage HCC. Even in the patients with advanced HCC,
the AFP levels may remain normal in 15 ~ 30% of all the
patients [5]. New specific markers, such as homeobox
gene Barx2, SMG-1, GOLM1 and et al. [6-8] have been
developed to improve the sensitivity, specificity, early
detection and prediction of prognosis of HCC. However,
the overall results have been unsatisfactory [9].
MicroRNAs (miRNAs) are reported as a group of small
non-coding RNAs that can function as endogenous RNA
interference to regulate expression of the targeted genes
[10-12]. To date, more than 1000 human miRNAs have
been identified and reported in the RNA database. Con-
sidering taht altered expression of some miRNAs contrib-
utes to human carcinogenesis, a part of these miRNAs
have been reported to be useful as potential biomarkers
for diagnosis, prognosis, and personalized therapy of
human cancers [13-15]. For example, aberrant miRNA
expression has been reported in HCC patients or cell lines
[16,17]. Given that blood samples can be easily obtained
and have the advantages of minimally invasive continuous
in vitrotesting and high reproducibility, determining
disease-specific circulating miRNAs to predict and
diagnose HCC has become the focus of many studies. A
number of researchers have reported the potential clinical
application of circulating miRNAs (such as miR-122, miR-
125b-5p, miR-223-3p, miR-15b and miR-130b) in the
diagnosis and prognosis of HCC [18-21]. Thus, further
investigation of aberrant miRNA expression could lead to
the discovery of novel miRNA biomarkers for HCC.
The objective of this study was to determine whether
altered miR-143 and miR-215 expression detected in the
serum could be a useful biomarker for the diagnosis of
HCC. Real-time quantitative reverse transcription poly-
merase chain reaction (RT-qPCR) was performed with
the following two goals of exploring whether: [1] serum
miR-143 and miR-215 are abnormally expressed in hepa-
titis and HCC; [2] miR-143 and miR-215 expression in
serum might diagnose hepatitis and HCC.
Methods
Ethics statement
Written informed consents were obtained from all the
participants in this study. The samples were processed
under approval of the Human Research Ethics Committee
of the Dalian Medical University, Shandong, China. Foridentification, the samples were codified A (for controls),
B (Hepatitis) and C (for HCC) followed by a codified
number to protect the privacy of individuals during all the
further molecular study.
Patients and samples
Between January 2013 and October 2013, a total of 340
serum samples (127 samples from controls, 118 samples
from hepatitis and 95 samples from HCC patients) were
collected at the First Affiliated Hospital of Dalian Medical
University and Dalian Municipal Central Hospital. All
of the HCC patients were diagnosed by liver biopsy or
by the findings of at least two radiological tests of HCC,
including abdominal ultrasound, magnetic resonance im-
aging (MRI), hepatic angiography and contrast-enhanced
dynamic computed tomography or by increased AFP
(AFP ≥200 μg/mL). Patients with secondary or recurrent
tumors, a history of other malignant tumors or being in-
cluded in other studies were excluded from this study. For
the 118 chronic hepatitis cases, the diagnosis was based
on the serum test. Serum hepatitis B surface antigens
(HBsAg) and anti-HCV antibody were assayed by micro-
particle enzyme immunoassay using commercial kits to
determine hepatitis B or hepatitis C infection. A total of
127 cancer-free controls were attached at the physical
examination center in the First Affiliated Hospital of
Dalian Medical University and matched with cases by age
within 5 years and sex. Controls that had clinical liver dis-
eases were excluded.
All subjects were asked to fill a questionnaire to investi-
gate the demographic characteristics, disease history and
the history of cancer and alcohol or tobacco use. The clin-
ical characteristics including tumor differentiation, tumor
size, metastasis, Child-Pugh class, chemotherapy and sur-
gery were collected from medical records.
RNA extraction
Total RNA extraction was performed using a miRcute
miRNA isolation kit (Tiangen, China), following the man-
ufacturer’s protocol for serum/plasma samples. Samples
were enriched for miRNAs in the extraction process. The
yields of total RNA were about 250 ng per 400 ml of
serum. The extracted RNA was reverse transcription to
cDNA as soon as possible. Reverse transcription was car-
ried out using an all-in-one miRNA first-strand cDNA
synthesis kit (Genecopoeia). The operation was conducted
following the manufacturer’s protocol for serum/plasma
samples.
Real-time PCR quantification of miRNA expression in serum
The expressions of miRNAs were quantified by TaqMan
miRNA assays (Applied Biosystems) following reverse
transcription (Tiangen, Chin) of 40 ng RNA. Reactions
were loaded onto a 96-well plate and run in duplicate on
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tems). The reactions were firstly incubated at 50°C for
20 seconds and then 95°C for 10 minutes, followed by
40 cycles of denaturation at 95°C for 15 seconds, then
1 minute of annealing/extension at 60°C. The ΔΔCT
method was used to determine relative number of copies
(RQ) of miRNA. The U6 was chosen as the endogenous
normalizer. The primers used for qRT-PCR in this study




The statistical analyses in this study was performed using
Statistical Program for Social Sciences (SPSS) software
17.0 (SPSS Inc., Chicago, USA). The t-test between two
groups were used to analyze the differences between
two groups. Nonparametric tests (the Wilcoxon-Mann–
Whitney test between two groups and the Kruskall-
Wallis test for three or more groups) were used to analyze
the relationship between the above miRNA expression
level and various clinicopathologic characteristics. The
receiver operating characteristic curve (ROC) analysis was
undertaken using the expression level for each miRNA in
the serum from cases and controls to assess the diagnostic
accuracy of each parameter. Using this approach, the area
under the ROC (AUC) identified optimal sensitivity and
specificity levels at which to distinguish normal individ-
uals. All the P values were shown two sided and a P value
of < 0.05 was considered statistically significant.
Results
Baseline and clinicopathologic characteristics of the patients
The baseline and clinicopathologic characteristics of the
all the participants are presented in Table 1. The median
ages of the control group, chronic hepatitis and HCC
patients at diagnosis were 52.58 ± 6.98 years, 53.12 ± 7.24
years, and 54.21 ± 6.95 years. Among the three groups,
there are no differences in the rates of hypertension,
diabetes, tobacco smoking and alcohol drinking among
the three groups (P > 0.05). Among the 95 HCC cases,
49 cases have a size over 5 cm while the others less than
5 cm. The tumor stages are 37 cases of TNM-I, 29 cases
of TNM-II, 26 cases of TNM-III and 13 cases of TNM-IV.
The lymph nodes and distant metastasis were observed in
12 and 8 cases, respectively.
MiR-143 and miR-215 expression in chronic hepatitis
and HCC
Serum miR-143 and miR-215 expression were detected
in 118 chronic hepatitis cases, 95 HCC cases and 127
controls normalized to RNU6B. As shown in Figure 1, we
found that the expression of serum miR-215 was distinctly
increased in chronic hepatitis compared with controls(mean ± SD: 6.79 ± 0.72 vs. 3.46 ± 0.37, P < 0.001). The
serum miR-143 was also increased in patients with HCC
compared with the controls (mean ± SD: 8.38 ± 0.87 vs.
3.46 ± 0.37, P < 0.001). The expression of serum miR-143
in chronic hepatitis (3.19 ± 0.51) and HCC group (5.13 ±
0.71) are both higher compared with the control group
(1.91 ± 0.44) (P < 0.001).
Diagnostic accuracy of serum miR-143 and miR-215 for
chronic hepatitis and HCC
The ROC curve analysis was used to analyze the diagnos-
tic accuracy of serum miR-143 and miR-215. ROC curve
analyses revealed that both serum miR-143 and miR-215
could serve as valuable biomarkers for chronic hepatitis
from healthy controls with an AUC (the areas under the
ROC curve) of 0.617 (95% CI: 0.512 – 0.758; P = 0.007)
and 0.802 (95% CI: 0.6701 – 0.947; P = 0.0006), respect-
ively (Figures 2A and 2B). At the cut-off value less than
2.14 for miR-143, the sensitivity and the specificity were
78% and 64%, respectively. At the cut-off value less than
4.23 for miR-215, the sensitivity and the specificity were
78% and 89%, respectively.
When the diagnostic value of miR-143 and miR-215 for
HCC were considered, both of the miRNAs are potential
biomarkers for the diagnosis of HCC. The results showed
that miR-143 and miR-215 could serve as valuable bio-
markers for HCC from healthy controls with an AUC
(the areas under the ROC curve) of 0.795 (95% CI: 0.682 –
0.915; P = 0.0001) and 0.816 (95% CI: 0.721 – 0.973; P <
0.0001), respectively (Figures 3A and 2B). At the cut-off
value less than 2.21 for miR-143, the sensitivity and the spe-
cificity were 73% and 83%, respectively. At the cut-off value
less than 4.62 for miR-215, the sensitivity and the specificity
were 80% and 91%, respectively.
Discussion
In this present study, we analyzed the expression of two
miRNAs, miR-143 and miR-215, in the serum among
the patients with healthy controls, chronic hepatitis and
HCC patients. We found that miR-143 and miR-215 ex-
pression was up-regulated in the serum samples from
patients with chronic hepatitis and HCC compared with
the controls. In addition, we conduct ROC analyses to
detect the potential application of miR-143 and miR-215
in the diagnoses of chronic hepatitis and HCC. Our results
showed that miR-143 and miR-215 might be potential bio-
markers for both hepatitis and HCC. Our current data in-
dicated that serum miR-143 and miR-215 expression
might be further evaluated as novel noninvasive diagnostic
biomarkers for HCC.
A lot of previous studies reported that miRNA expression
is aberrant through HCC development; however, most of
these studies focused on the expression of miRNAs in
HCC tissues and cell lines. For example, a previous study
Table 1 Characteristics of hepatocellular carcinoma patients, and controls
Clinicopathological features No. of participants Groups P
Control (n = 127) Hepatitis (n = 118) HCC (n = 95)
Mean age (year,mean ± SD) 340 52.58 ± 6.98 53.12 ± 7.24 54.21 ± 6.95 0.634
Gender
Male 184 71 65 60 0.217
Female 156 56 53 35
Hypertension
No 120 42 42 36 0.129
Yes 220 85 75 59
Diabetes mellitus
No 302 112 105 85 0.863
Yes 38 15 13 10
Tobacco smoking
No 192 74 68 62 0.207
Yes 148 53 65 33
Alcohol consumption
No 238 89 82 77 0.326















HCC: Hepatocellular carcinoma; LN: Lymph nodes.
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titis B virus-related HCC. Based on the data of 11 pairs of
HCC and matched non-tumorous tissues from 11 HBV
infection patients, miR-96, miR-183, and miR-196a were
up-regulated significantly, while let-7c and miR-138 were
down-regulated [22]. Xiao et al. conduct a follow-up study
and the results revealed that miR‑200a was frequently
downregulated in HCC. In addition, multivariate analysis
confirmed that miR‑200a was significantly associated with
the overall survival of HCC patients [23]. In an other
study, Yu et al. found that miR-424 was down-regulated
in HCC cell lines compared a normal hepatocytes and
in vitro studies showed that miR-424 is effective in the
neoplasty of HCC [24].Although tissue miRNAs can provide an accurate diag-
nosis for various types of cancer, the difficulty in collecting
tissue samples limits its application for the detection of
cancer biomarkers. Acquiring tissue samples is an invasive
procedure and depends on surgical sections after initial
clinical classification [25]. The search for noninvasive tools
for the diagnosis of cancer has long been a goal of many
researchers, and much of the interest has been on the cir-
culation of nucleic acids in plasma and serum. Compared
with DNA and mRNA, circulating miRNAs show re-
markable stability after prolonged incubation at room
temperature and/or multiple freezing-thawing processes.
However, the protective mechanism of circulating miR-
NAs is still unknown. Some investigators reported that
Figure 1 Relative expression levels of miR-143 and miR-215 in
127 controls, 118 hepatitis and 95 HCC patients. The expression
levels were determined using a qRT-PCR assay, and the relative
expression data were analyzed using the 2- CT method. All of the
assays were performed in triplicate. U6 was used as an
internal control.
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(Ago2)-miRNA complexes that could avoid RNase
digestion [26].
Nowadays, there are increasing studies being con-
ducted to identify specific circulating miRNAs in the
diagnosis of HCC. Giray et al. conducted a study to in-
vestigate the potential of certain serum/plasma miRNAs
as novel non-invasive biomarkers for early diagnosis of
HBV related HCC. Through comprehensive tests of 94
plasma samples (28 control and 66 patient plasma
samples), a series of related miRNAs were reported in
the study and the expression of miR-223 was the mostFigure 2 Receiver-operatorcharacteristic (ROC) curves of the A) miR-1significant. Microvesicles (MVs) packaged with miRNAs
were reported to be released mainly from tumor cells. Sun
et al. conduct expression profiles to detect the differently
expressed miRNAs. The results showed that a total of 242
aberrantly expressed miRNAs were identified in HCC-MVs
compared with CHB-MVs and the control. Among them,
115 miRNAs were up-expressed with up to 31 fold differ-
ence (miR-671-5p) and 127 were down-expressed with up
to 0.041 fold difference (miR-432) in HCC [27]. A potential
correlation was also evaluated between miR-101 expression
and the clinicopathological features and prognosis of HCC
patients. It was reported that miR-101 was down-regulated
in HBV-related HCC tissues compared with adjacent non-
cancerous tissues. Furthermore, the miR-101 levels in
these tissues from HCC patients were significantly lower
than those in tissues from control subjects [28].
In this present study, we focus on the diagnostic value
of miR-143 and miR-215 for the chronic hepatitis and
HCC. Previous reports have shown that the expression
of miR-143 is extremely down-regulated in colorectal
cancer, lung, bladder, and gastric cancers [29-31]. While
it is reported the expression of miR-143 is up-regulated
in pancreatic stellate cells cancer and esophageal cancer
[32,33]. There are few reports about the relationship be-
tween miR-143 expression and the diagnosis of HCC.
Up to now, only one study reported the association be-
tween miR-143 and HCC. Zhang et al. reported that the
levels of miRNA-143 (miR-143) are dramatically increased
in metastatic HBV-HCC of both p21-HBx transgenic
mice and HCC patients. Advanced study showed that
up-regulation of miR-143 expression promotes cancer
cell invasion/migration and tumor metastasis by repres-
sion of FNDC3B expression [34]. The association between43 and B) miR-215 for the chronic hepatitis.
Figure 3 Receiver-operatorcharacteristic (ROC) curves of the A) miR-143 and B) miR-215 for the hepatocellular carcinoma.
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reported that miR-215 had a significantly lower expression
in nephroblastomas regardless of the subtype compared
with mature kidney measured by quantitative real-
time-PCR [35]. White et al. performed experimental
and bioinformatic analyses to explore the involvement
of miR-215 in renal cell carcinoma progression and
metastasis. In vitro study showed that miR-215 might
contribute to kidney cancer metastasis through different
biological processes [36]. In a previous study, miR-215
was reported to be up-regulated in HCC cancer cases
[37]. Ishida et al. reported that using miRNA array ana-
lysis, miR-192/miR-215, miR-194, miR-320, and miR-491
were identified as being altered by HCV infection. Among
them, miR-192/miR-215 and miR-491 were capable of en-
hancing replication of the HCV replicon as well as HCV
itself [38]. To our best knowledge, this is the first study
that reports the association between miR-143/miR-215
and HCC. More related studies are wanted to investigate
to clinical application and detailed mechanisms.
Recent years, more and more studies raised diagnostic
and prognostic application of miRNAs in different diseases,
including cancer. Their application to body specimens
from blood to tissues has been helpful for appreciating
their use in the clinical context [39]. Our results showed
that serum miR-143 and miR-215 were commonly up-
regulated in chronic hepatitis and HCC patients, sug-
gesting miR-143 and miR-215 may be new potential
diagnostic biomarkers and targets of chronic hepatitis
and HCC. However, as a case–control study without a
long-time follow-up, the prognostic effect of the two
miRNAs could not be detected in this study. A follow-up of
this cohort would be reportedand more advanced analyses
would be conducted.Conclusion
In conclusion, the expression of miR-143 and miR-215
in serum were significantly up-regulated in patients with
chronic hepatitis and HCC. Due to its reasonable sensitiv-
ity and specificity for both diseases, miR-143 and miR-215
could be as potential circulating biomarkers. Our work
will serve as a basis for further investigation, preferably
large-scale validation in clinical trials, before serum miR-
NAs can be used as a routine screening tool for HCC.
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